Phase 1 Study of Ropidoxuridine for Increasing Gastrointestinal Cancer Radiation Sensitivity

Share this content:
Researchers are assessing the toxicity profile and efficacy of ropidoxuridine in patients with metastatic gastrointestinal cancer unlikely to respond to radiotherapy.
Researchers are assessing the toxicity profile and efficacy of ropidoxuridine in patients with metastatic gastrointestinal cancer unlikely to respond to radiotherapy.

Title: Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers1

Principal Investigator: Timothy Kinsella, MD, Rhode Island Hospital

Description: For this open label, dose-escalation phase 1 study (ClinicalTrials.gov Identifier: NCT02158234), researchers are assessing the toxicity profile and efficacy of ropidoxuridine in patients with metastatic gastrointestinal cancer unlikely to respond to radiation. Ropidoxuridine may sensitize cancer cells to radiation therapy.

Patients with stage II to IVB gastrointestinal tumors (bile duct carcinoma, esophageal, pancreatic, colon, gastric, liver, rectal, or small intestinal cancer) will receive oral ropidoxuridine daily for 28 days. On day 8, patients will receive intensity-modulated radiation therapy 5 days a week for 3 weeks. Ropidoxuridine will be administered 30 minutes to 2 hours prior to radiation therapy.

The primary objective is to determine a maximum tolerated dose of ropidoxuridine. Secondary objectives include anti-tumor activity.

The estimated study enrollment is 30 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02381561.

Status: Open and recruiting patients as of November 20, 2017.

This study is sponsored by the National Cancer Institute (NCI).

Reference

  1. ClinicalTrials.gov. Ropidoxuridine in treating patients with advanced gastrointestinal cancer undergoing radiation therapy. NCT02381561. https://clinicaltrials.gov/ct2/show/NCT02381561. Accessed November 21, 2017. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters